Comment from Dentons Bingham Greenebaum LLP, submitting on behalf of a client, who is a state-licensed 503A compounding pharmacy
AnonymousSupportBusiness
Summary: A state-licensed 503A compounding pharmacy is submitting a comment in support of the proposed nomination of MOTS-c (free base and acetate) as a bulk drug substance. The commenter provides extensive scientific literature and physicochemical data to argue that MOTS-c is a synthetic peptide with potential therapeutic applications in metabolic and age-related diseases that can be safely and reproducibly compounded.
The attached materials are being submitted on behalf of a state-licensed 503A compounding pharmacy. The materials were prepared by a licensed pharmacist in consultation with other licensed medical professionals and are being submitted as a public comment in support of the proposed nomination. The materials are not intended to constitute legal advice and were neither prepared by nor express the opinions of Dentons Bingham Greenebaum LLP.